Cullinan Therapeutics (CGEM) Competitors $7.70 -0.14 (-1.79%) Closing price 04:00 PM EasternExtended Trading$7.70 0.00 (0.00%) As of 06:17 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock CGEM vs. ADPT, SPRY, CNTA, TARS, BEAM, SRPT, ARQT, IMCR, SDGR, and EVOShould you be buying Cullinan Therapeutics stock or one of its competitors? The main competitors of Cullinan Therapeutics include Adaptive Biotechnologies (ADPT), ARS Pharmaceuticals (SPRY), Centessa Pharmaceuticals (CNTA), Tarsus Pharmaceuticals (TARS), Beam Therapeutics (BEAM), Sarepta Therapeutics (SRPT), Arcutis Biotherapeutics (ARQT), Immunocore (IMCR), Schrodinger (SDGR), and Evotec (EVO). These companies are all part of the "pharmaceutical products" industry. Cullinan Therapeutics vs. Its Competitors Adaptive Biotechnologies ARS Pharmaceuticals Centessa Pharmaceuticals Tarsus Pharmaceuticals Beam Therapeutics Sarepta Therapeutics Arcutis Biotherapeutics Immunocore Schrodinger Evotec Adaptive Biotechnologies (NASDAQ:ADPT) and Cullinan Therapeutics (NASDAQ:CGEM) are both small-cap medical companies, but which is the superior stock? We will contrast the two companies based on the strength of their valuation, risk, profitability, institutional ownership, analyst recommendations, dividends, media sentiment and earnings. Do insiders and institutionals hold more shares of ADPT or CGEM? 99.2% of Adaptive Biotechnologies shares are owned by institutional investors. Comparatively, 86.3% of Cullinan Therapeutics shares are owned by institutional investors. 6.4% of Adaptive Biotechnologies shares are owned by insiders. Comparatively, 7.2% of Cullinan Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company will outperform the market over the long term. Which has preferable valuation & earnings, ADPT or CGEM? Adaptive Biotechnologies has higher revenue and earnings than Cullinan Therapeutics. Adaptive Biotechnologies is trading at a lower price-to-earnings ratio than Cullinan Therapeutics, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioAdaptive Biotechnologies$178.96M10.03-$159.49M-$0.96-12.31Cullinan TherapeuticsN/AN/A-$167.38M-$2.91-2.65 Do analysts recommend ADPT or CGEM? Adaptive Biotechnologies presently has a consensus price target of $10.57, suggesting a potential downside of 10.56%. Cullinan Therapeutics has a consensus price target of $30.00, suggesting a potential upside of 289.61%. Given Cullinan Therapeutics' stronger consensus rating and higher probable upside, analysts plainly believe Cullinan Therapeutics is more favorable than Adaptive Biotechnologies.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Adaptive Biotechnologies 0 Sell rating(s) 1 Hold rating(s) 6 Buy rating(s) 0 Strong Buy rating(s) 2.86Cullinan Therapeutics 0 Sell rating(s) 0 Hold rating(s) 5 Buy rating(s) 0 Strong Buy rating(s) 3.00 Which has more risk & volatility, ADPT or CGEM? Adaptive Biotechnologies has a beta of 1.83, indicating that its stock price is 83% more volatile than the S&P 500. Comparatively, Cullinan Therapeutics has a beta of -0.08, indicating that its stock price is 108% less volatile than the S&P 500. Does the media prefer ADPT or CGEM? In the previous week, Adaptive Biotechnologies had 9 more articles in the media than Cullinan Therapeutics. MarketBeat recorded 12 mentions for Adaptive Biotechnologies and 3 mentions for Cullinan Therapeutics. Cullinan Therapeutics' average media sentiment score of 0.96 beat Adaptive Biotechnologies' score of 0.44 indicating that Cullinan Therapeutics is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Adaptive Biotechnologies 4 Very Positive mention(s) 1 Positive mention(s) 5 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Neutral Cullinan Therapeutics 1 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Is ADPT or CGEM more profitable? Cullinan Therapeutics has a net margin of 0.00% compared to Adaptive Biotechnologies' net margin of -74.84%. Cullinan Therapeutics' return on equity of -29.47% beat Adaptive Biotechnologies' return on equity.Company Net Margins Return on Equity Return on Assets Adaptive Biotechnologies-74.84% -62.79% -24.55% Cullinan Therapeutics N/A -29.47%-28.19% SummaryAdaptive Biotechnologies beats Cullinan Therapeutics on 8 of the 15 factors compared between the two stocks. Get Cullinan Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for CGEM and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding CGEM and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart CGEM vs. The Competition Export to ExcelMetricCullinan TherapeuticsMED IndustryMedical SectorNASDAQ ExchangeMarket Cap$462.67M$2.99B$5.61B$9.11BDividend YieldN/A2.39%5.24%4.01%P/E Ratio-2.6520.5827.9620.25Price / SalesN/A292.00430.8999.65Price / CashN/A42.8637.4658.16Price / Book0.767.638.045.49Net Income-$167.38M-$55.05M$3.18B$250.27M7 Day Performance-1.41%8.54%3.72%4.78%1 Month Performance-14.25%5.38%3.72%7.20%1 Year Performance-52.41%2.35%29.92%17.27% Cullinan Therapeutics Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)CGEMCullinan Therapeutics1.6459 of 5 stars$7.70-1.8%$30.00+289.6%-51.1%$462.67MN/A-2.6530News CoverageADPTAdaptive Biotechnologies2.9657 of 5 stars$11.65-1.2%$10.57-9.3%+245.1%$1.79B$178.96M-12.14790SPRYARS Pharmaceuticals3.2464 of 5 stars$17.45-4.1%$31.00+77.7%+71.9%$1.79B$89.15M-109.0690Positive NewsHigh Trading VolumeCNTACentessa Pharmaceuticals3.2417 of 5 stars$13.14+0.1%$27.89+112.2%+48.0%$1.75B$6.85M-7.26200TARSTarsus Pharmaceuticals2.0462 of 5 stars$40.51+0.4%$66.67+64.6%+46.0%$1.70B$182.95M-14.8450Positive NewsBEAMBeam Therapeutics2.1396 of 5 stars$17.01+1.3%$48.75+186.6%-8.1%$1.69B$63.52M-3.69510SRPTSarepta Therapeutics4.7075 of 5 stars$17.10-0.1%$60.88+256.0%-87.2%$1.68B$1.90B-6.361,372Trending NewsAnalyst ForecastAnalyst RevisionHigh Trading VolumeARQTArcutis Biotherapeutics1.9523 of 5 stars$14.02+2.0%$18.80+34.1%+55.7%$1.64B$196.54M-13.48150News CoverageIMCRImmunocore1.5004 of 5 stars$31.38+0.8%$58.89+87.7%-6.8%$1.56B$310.20M-72.98320News CoverageSDGRSchrodinger2.4198 of 5 stars$20.12-2.4%$32.80+63.0%+5.5%$1.51B$207.54M-7.65790Positive NewsHigh Trading VolumeEVOEvotec2.0228 of 5 stars$4.20+1.0%$5.93+41.3%-20.0%$1.48B$862.40M0.004,827 Related Companies and Tools Related Companies ADPT Alternatives SPRY Alternatives CNTA Alternatives TARS Alternatives BEAM Alternatives SRPT Alternatives ARQT Alternatives IMCR Alternatives SDGR Alternatives EVO Alternatives Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:CGEM) was last updated on 7/11/2025 by MarketBeat.com Staff From Our PartnersINVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting OffRight now, we’re witnessing a monumental shift in the world.Traders Agency | SponsoredMarket Panic: Trump Just Dropped a Bomb on Your Stockstock Market Panic: Trump Just Dropped a Bomb on Your Stocks The market is in freefall—and Trump's new tarif...American Alternative | SponsoredThis Signal Only Flashes Once Every 4 Years – And It Just TriggeredThis same signal has appeared twice before in the past 8 years — both times, it kicked off major moves in cryp...Crypto Swap Profits | SponsoredPresidential Bombshell: $150T Resource to Be Released as soon as this Summer?Something extraordinary is happening in Washington. For the first time in over a century, a sitting Preside...Paradigm Press | SponsoredTrump’s treachery Trump’s Final Reset Inside the shocking plot to re-engineer America’s financial system…and why you need to ...Porter & Company | Sponsored[No Brainer Gold Play]: “Show me a better investment.”A Historic Gold Announcement Is About to Rock Wall Street? For months, sharp-eyed analysts have watched the...Golden Portfolio | SponsoredGoogle did what!?!?A new technology has sparked a modern-day gold rush in Silicon Valley. OpenAI’s Sam Altman invested $375M. Bil...Stansberry Research | SponsoredBanks aren’t ready for this altcoin—are you?Our expert analysts have identified a $100 billion gap in the crypto market. Only one project is perfectly ...Crypto 101 Media | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Cullinan Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Cullinan Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
